الصفحة الرئيسية>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> Akt>>Uprosertib hydrochloride

Uprosertib hydrochloride (Synonyms: GSK2141795 (hydrochloride))

رقم الكتالوجGC37859

هيدروكلوريد Uprosertib (GSK2141795 hydrochloride) هو مثبط قوي وانتقائي pan-Akt بقيم IC50 180/328/38 نانومتر لـ Akt1 / Akt2 / Akt3 ، على التوالي

Products are for research use only. Not for human use. We do not sell to patients.

Uprosertib hydrochloride التركيب الكيميائي

Cas No.: 1047635-80-2

الحجم السعر المخزون الكميّة
5mg
89٫00
متوفر
10mg
144٫00
متوفر
50mg
510٫00
متوفر
100mg
667٫00
متوفر
200mg
1159٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective pan-Akt inhibitor with IC50 values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively. Akt1|180 nM (IC50)|Akt2|328 nM (IC50)|Akt3|38 nM (IC50)|CDK7|2100 nM (IC50)|ROCK1|1570 nM (IC50)|ROCK2|1850 nM (IC50)

Uprosertib inhibits Akt1/2/3 with the Kd values of 16/49/5 nM, respectively. Uprosertib potently inhibits only the PKC family members PRKACA and PRKACB as well as the cGMP-dependent protein kinase PRKG1 aqpart from the Akts. Protein targets that bind Uprosertib in the lysate show a dose-dependent reduction in binding to the kinobeads, while proteins unaffected by the drug show no reduction in binding[1].

[1]. Pachl F, et al. Characterization of a chemical affinity probe targeting Akt kinases. J Proteome Res. 2013 Aug 2;12(8):3792-800.

مراجعات

Review for Uprosertib hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 39 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Uprosertib hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.